FDA probes deaths linked to Sarepta's gene therapy for muscular dystrophy
THE U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics' gene therapy, Elevidys.
In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. The patients who died were a 16-year-old, weighing 70 kilograms, and a 15-year-old, weighing 50 kilograms. Both boys were non-ambulatory and their deaths occurred within 90 days after treatment, the company said in an investor call last week.
The two patients showed signs of acute liver failure and were hospitalized less than two months after treatment with Elevidys, the health regulator said on Tuesday. It added that it is evaluating the need for further regulatory action.
Sarepta said in an email to Reuters, 'The FDA communication was triggered by our report to the FDA and our suggested update to the label to include information relating to the recent events.'
The U.S. prescribing information for Elevidys warns of acute liver injury but does not mention liver failure or death.
Elevidys, approved by the FDA in 2024 for ambulatory Duchenne muscular dystrophy patients aged four and older, is the only gene therapy available for the disease. It carries a known risk of liver damage and was conditionally approved for non-ambulatory patients despite failing to meet the main goal in a late-stage study.
Sarepta said earlier this month it was investigating both cases independently and in relation to each other to identify any common risk factors.
The company has suspended its Elevidys sales forecast for 2025, halted shipments to non-ambulatory patients and is working with regulators on a new treatment plan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
9 hours ago
- Barnama
Fortrea, Emery Pharma Team Up On Rifampin Safety Testing For Clinical Trials
BUSINESS KUALA LUMPUR, June 25 (Bernama) -- Fortrea, a global contract research organisation (CRO), has announced a strategic collaboration with Emery Pharma to provide rapid impurity testing of rifampin used in drug-drug interaction (DDI) studies. In a statement, Fortrea said the partnership will enable testing for 1-methyl-4-nitrosopiperazine (MNP), a nitrosamine impurity, ensuring levels remain below the acceptable intake limit set by the United States Food and Drug Administration (FDA). Fortrea Chief Medical Officer and President of Clinical Pharmacology Services, Dr Oren Cohen said the partnership would help accelerate early-phase clinical trials by providing certified rifampin for use in DDI studies and enhance data quality. 'This collaboration reflects our shared commitment to smarter study design and greater participant safety,' he said. Meanwhile, Emery Pharma Chief Executive Officer, Dr Ron Najafi said the collaboration would contribute to safer and more efficient drug development, adding that the company specialises in solving complex analytical challenges in compliance with regulatory standards. Fortrea selected Emery Pharma based on its expertise in analytical and bioanalytical testing under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP) standards. The new testing service is now available to Fortrea customers involved in clinical pharmacology trials, with study designs tailored to FDA requirements. Rifampin, a widely used antibiotic and a preferred agent in DDI studies due to its safety and tolerability, had previously come under scrutiny after the FDA found that MNP levels in tested batches exceeded acceptable limits. However, the agency revised its guidance in 2023, allowing the continued use of rifampin under updated thresholds.
The Sun
14 hours ago
- The Sun
FDA probes deaths linked to Sarepta's gene therapy for muscular dystrophy
THE U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics' gene therapy, Elevidys. In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. The patients who died were a 16-year-old, weighing 70 kilograms, and a 15-year-old, weighing 50 kilograms. Both boys were non-ambulatory and their deaths occurred within 90 days after treatment, the company said in an investor call last week. The two patients showed signs of acute liver failure and were hospitalized less than two months after treatment with Elevidys, the health regulator said on Tuesday. It added that it is evaluating the need for further regulatory action. Sarepta said in an email to Reuters, 'The FDA communication was triggered by our report to the FDA and our suggested update to the label to include information relating to the recent events.' The U.S. prescribing information for Elevidys warns of acute liver injury but does not mention liver failure or death. Elevidys, approved by the FDA in 2024 for ambulatory Duchenne muscular dystrophy patients aged four and older, is the only gene therapy available for the disease. It carries a known risk of liver damage and was conditionally approved for non-ambulatory patients despite failing to meet the main goal in a late-stage study. Sarepta said earlier this month it was investigating both cases independently and in relation to each other to identify any common risk factors. The company has suspended its Elevidys sales forecast for 2025, halted shipments to non-ambulatory patients and is working with regulators on a new treatment plan.
Malaysian Reserve
18-06-2025
- Malaysian Reserve
SEEKING DOGS WITH EXTREME FEAR OF THUNDERSTORMS FOR VETERINARY STUDY IN FLORIDA
Multiple Clinics Participating in Study Evaluating an Investigational Medication With the Goal of Achieving the Medication's Approval by FDA RALEIGH, N.C., June 17, 2025 /PRNewswire/ — Dog owners in Florida—the storm capital of the U.S—now have the opportunity to have their dogs screened for possible inclusion in a clinical study evaluating a potential treatment for severe thunderstorm aversion. The study is evaluating an investigational oral medication given twice-daily during storm season that could offer round-the-clock relief. Participation is free, and qualifying dogs receive all study-related care–including evaluations, diagnostic testing, exams, and medication (or placebo) at no cost. Marilyn Bonner says her dog was 'skittish' of storms and loud noises when living in Pennsylvania, but upon moving to Florida, her Boxer developed intense anxiety. 'Nothing prepared us for the thunderstorms in Florida. They're so intense and so frequent. As soon as one rolls in, she'll start panting and severely shaking. It's heartbreaking.' Dogs With Thunderstorm Aversion Are Suffering Dogs with severe thunderstorm aversion often display their intense fear by hiding, cowering, destructiveness, trembling/shaking, self-harm, and more. Sadly, the fear may begin hours before a storm arrives, and in some cases, take days for dogs to recover. 'During a thunderstorm, my dog never leaves my side; she's there shaking, drooling, and practically hyperventilating. There are times I've thought she was going to have a heart attack,' says Jill Powers, of Southwest Florida. 'I just feel so terrible for her.' In a published study, nearly 50% of dog owners reported their dogs show fear when exposed to noises. What Dogs Can Participate?In order to be eligible, dogs must show signs of thunderstorm aversion, weigh at least 8.8 lbs., be in good general health, and meet certain other criteria. Interested dog owners can visit to see if there's a participating veterinary site nearby and complete a short pre-screening questionnaire. Take Action NowThe study only runs a few months during Florida's storm season, so pet owners interested in signing up their dogs should act quickly. Participation offers pet owners a chance to help their dogs, support research that could lead to a medication approved by the Food & Drug Administration's Center for Veterinary Medicine, and benefit generations of dogs in the future. To learn more, visit About VisionaireVisionaire Research & Education supports patient recruitment for veterinary clinical studies, helping veterinary pharmaceutical Sponsors speed new pet medications to market. The Company's number one priority is helping dogs, cats, and horses — and their owners — experience a better quality of life through innovative treatments and solutions. The pivotal studies Visionaire supports can be a way to gain access to quality diagnostics and veterinary care — and investigational therapies that often aren't available anywhere else — all at no cost to pet owners. For more information, visit Contact: Megan Hepp, 919-293-0243 x 202; megan@
